Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 8/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.43 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.36 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.36 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 4/20 | 0.37 |
| ▸ | HTR2B | P41595 | 5/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173319 | 0.89 | HTR2A (0.51) | HTR2CHTR2APNMTDRD2SLC6A2 | |
| Hydrochloric Acid SCHEMBL5317898 | 0.88 | HTR2A (0.50) | HTR2CHTR2APNMTDRD2SLC6A2 | |
| Phosphoric Acid SCHEMBL174685 | 0.87 | HTR2A (0.44) | HTR2CHTR2APNMTDRD2SLC6A2 | |
| Malonic Acid SCHEMBL174326 | 0.86 | HTR2A (0.41) | HTR2CHTR2APNMTDRD2SLC6A2 | |
| Glycolic Acid SCHEMBL174591 | 0.83 | HTR2A (0.41) | HTR2CHTR2APNMTDRD2SLC6A2 | |
| Succinic Acid SCHEMBL175159 | 0.83 | HTR2A (0.41) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| Adipic Acid SCHEMBL173981 | 0.81 | L3MBTL1 (0.41) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| Alpha-Ketoglutaric Acid SCHEMBL174485 | 0.78 | HTR2A (0.37) | HTR2CHTR2ADRD2SLC6A2SLC6A4 | |
| Citric Acid SCHEMBL173747 | 0.77 | SLC13A5 (0.39) | HTR2CHTR2A | |
| SCHEMBL9058489 | 0.74 | HTR2A (0.62) | HTR2CHTR2APNMTDRD2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |